Ezetimibe combined with standard diet and exercise therapy improves insulin resistance and atherosclerotic markers in patients with metabolic syndrome

Journal of Diabetes Investigation

Volumn 6, Issue 3, 2015, Pages 325-333

  Ohbu Murayama, Kyoko ^a   Adachi, Hisashi ^b   Hirai, Yuji ^a   Enomoto, Mika ^a   Fukami, Ako ^a   Obuchi, Aya ^a   Yoshimura, Ayako ^a   Nakamura, Sachiko ^a   Nohara, Yume ^a   Nakao, Erika ^a   Umeki, Yoko ^a   Fukumoto, Yoshihiro ^a  

^a Department of Medicine Division of Cardiovascular Medicine   (Japan)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Ezetimibe; Insulin resistance; Metabolic syndrome

Indexed keywords

ANTILIPEMIC AGENT; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BODY MASS; BODY WEIGHT; COHORT ANALYSIS; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIET THERAPY; FEMALE; HUMAN; INSULIN RESISTANCE; JAPANESE (PEOPLE); KINESIOTHERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL EXAMINATION; METABOLIC SYNDROME X; OBSERVATIONAL STUDY; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84928279929     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/jdi.12298     Document Type: Article

References (37)

1. Knopp RH, Dujovne CA, Le Beaut A, et al. Ezetimibe Study Group. Evaluation of efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolaemia: a pooled analysis from two controlled phase III clinical studies. Int J Clin Pract 2003; 57: 363-368.
2. Denke M, Pearson T, Mcbride P, et al. Ezetimibe added to ongoing statin therapy improves LDL-C goal attainment and lipid profile in patients with diabetes or metabolic syndrome. Diab Vasc Dis Res 2006; 3: 93-102.
3. Hajer GR, Dallinga-Thie GM, van Vark-van der Zee LC, et al. The effect of statin alone or in combination with ezetimibe on postprandial lipoprotein composition in obese metabolic syndrome patients. Atherosclerosis 2009; 202: 216-224.
4. Winkler K, Schewe T, Pütz G, et al. Fluvastatin/fenofibrate vs. simvastatin/ezetimibe in patients with metabolic syndrome: different effects on LDL-profiles. Eur J Clin Invest 2009; 39: 463-470.
5. Robinson JG, Ballantyne CM, Grundy SM, et al. Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET Study). Am J Cardiol 2009; 103: 1694-1702.
6. Goldberg RB, Guyton JR, Mazzone T, et al. Relationships between metabolic syndrome and other baseline factors and the efficacy of ezetimibe/simvastatin and atorvastatin in patients with type 2 diabetes and hypercholesterolemia. Diabetes Care 2010; 33: 1021-1024.
7. Conard S, Bays H, Leiter LA, et al. Ezetimibe added to atorvastatin compared with doubling the atorvastatin dose in patients at high risk for coronary heart disease with diabetes mellitus, metabolic syndrome or neither. Diabetes Obes Metab 2010; 12: 210-218.
8. Miller M, DiNicolantonio JJ, Can M, et al. The effects of ezetimibe/simvastatin versus simvastatin monotherapy on platelet and inflammatory biomarkers in patients with metabolic syndrome. Cardiology 2013; 125: 74-77.
9. Rosen JB, Jimenez JG, Pirags V, et al. A comparison of efficacy and safety of an ezetimibe/simvastatin combination compared with other intensified lipid-lowering treatment strategies in diabetic patients with symptomatic cardiovascular disease. Diab Vasc Dis Res 2013; 10: 277-286.
10. Bays HE, Shah A, Macdonell G, et al. Effects of coadministered ezetimibe plus fenofibrate in mixed dyslipidemic patients with metabolic syndrome. Metab Syndr Relat Disord 2011; 9: 135-142.
11. Averna M, Missault L, Vaverkova H, et al. Lipid-altering efficacy of switching to ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk patients with and without metabolic syndrome. Diab Vasc Dis Res 2011; 8: 262-270.
12. Ichimori S, Shimoda S, Goto R, et al. Ezetimibe improves glucose metabolism by ameliorating hepatic function in Japanese patients with type 2 diabetes. J Diabetes Invest 2012; 3: 179-184.
13. Tamaki N, Ueno H, Morinaga Y, et al. Ezetimibe ameliorates atherosclerotic and inflammatory markers, atherogenic lipid profiles, insulin sensitivity, and liver dysfunction in Japanese patients with hypercholesterolemia. J Atheroscler Thromb 2012; 19: 532-538.
14. Yagi S, Akaike M, Aihara KI, et al. Ezetimibe ameliorates metabolic disorders and microalbuminuria in patients with hypercholesterolemia. J Atheroscler Thromb 2010; 17: 173-180.
15. Nochioka K, Tanaka S, Miura M, et al. Ezetimibe improves endothelial function and inhibits Rho-kinase activity associated with inhibition of cholesterol absorption in humans. Circ J 2012; 76: 2023-2030.
16. Hirai Y, Geleijnse JM, Adachi H, et al. Systolic blood pressure predicts cardiovascular mortality in a farming but not in a fishing community. - A 40-year follow up of the Japanese cohorts of the Seven Countries Study -. Circ J 2011; 75: 1890-1896.
17. Hino A, Adachi H, Toyomasu K, et al. Very long chain N-3 fatty acids intake and carotid atherosclerosis: an epidemiological study evaluated by ultrasonography. Atherosclerosis 2004; 176: 145-149.
18. Kumagai E, Adachi H, Jacobs DR Jr, et al. Plasma aldosterone levels and development of insulin resistance: prospective study in a general population. Hypertension 2011; 58: 1043-1048.
19. Otsuka M, Adachi H, Jacobs DR Jr, et al. Serum hepatocyte growth factor and cancer mortality in an apparently healthy Japanese population. J Epidemiol 2012; 22: 395-401.
20. Yokoi K, Adachi H, Hirai Y, et al. Plasma endothelin-1 level is a predictor of 10-year mortality in a general population: the Tanushimaru study. Circ J 2012; 76: 2779-2784.
21. Pignoli P, Tremoli E, Poli A, et al. Intimal plus medial thickness of the arterial wall: a direct measurements with ultrasound imaging. Circulation 1986; 74: 1399-1406.
22. Yamasaki Y, Kodama M, Nishizawa H, et al. Carotid intima-media thickness in Japanese type 2 diabetic subjects. Diabetes Care 2000; 23: 1310-1315.
23. Nakajima K, Saito T, Tamura A, et al. Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apo B-100 and anti apo A-I immunoaffinity mixed gels. Clin Chim Acta 1993; 223: 53-71.
24. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
25. Zimmet P, Magliano D, Matsuzawa Y, et al. The metabolic syndrome: a global public health problem and a new definition. J Atheroscler Thromb 2005; 12: 295-300.
26. Matsuzawa Y. Metabolic syndrome - Definition and diagnostic criteria in Japan. J Atheroscler Thromb 2005; 12: 301.
27. Hiramitsu S, Ishiguro Y, Matsuyama H, et al. The effects of ezetimibe on surrogate markers of cholesterol absorption and synthesis in Japanese patients with dyslipidemia. J Atheroscler Thromb 2010; 17: 106-114.
28. Takase H, Dohi Y, Okado T, et al. Effects of ezetimibe on visceral fat in the metabolic syndrome: a randomized controlled study. Eur J Clin Invest 2012; 42: 1287-1294.
29. Kotani K, Sakane N, Taniguchi N. Effect of ezetimibe on remnant-like particle cholesterol in subjects with metabolic syndrome. Med Princ Pract 2012; 21: 134-138.
30. Deushi M, Nomura M, Kawakami A, et al. Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome. FEBS Lett 2007; 581: 5664-5670.
31. Dagli N, Yavuzkir M, Karaca I. The effects of high dose pravastatin and low dose pravastatin and ezetimibe combination therapy on lipid, glucose metabolism and inflammation. Inflammation 2007; 30: 230-235.
32. Kikuchi K, Nezu U, Inazumi K, et al. Double-blind randomized clinical trial of the effects of ezetimibe on postprandial hyperlipidemia and hyperglycaemia. J Atheroscler Thromb 2012; 19: 1093-1101.
33. Ridker PM, Pradhan A, MacFadyen JG, et al. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 2012; 380: 565-571.
34. Kurobe H, Aihara K, Higashida M, et al. Ezetimibe monotherapy ameliorates vascular function in patients with hypercholesterolemia through decreasing oxidative stress. J Atheroscler Thromb 2011; 18: 1080-1089.
35. Haring R, Baumeister SE, Völzke H, et al. Prospective inverse associations of sex hormone concentrations in men with biomarkers of inflammation and oxidative stress. J Androl 2012; 33: 944-950.
36. Sato K, Nakano K, Katsuki S, et al. Dietary cholesterol oxidation products accelerate plaque destabilization and rupture associated with monocyte infiltration/activation via the MCP-1-CCR2 pathway in mouse brachiocephalic arteries: therapeutic effects of Ezetimibe. J Atheroscler Thromb 2012; 19: 986-998.
37. Hayek S, Canepa Escaro F, Sattar A, et al. Effect of ezetimibe on major atherosclerotic disease events and all-cause mortality. Am J Cardiol 2013; 111: 532-539.